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Breast cancer is a leading cause of cancer death, 
largely because of metastatic disease (Jemal et al., 
2011). There are a large numbers of clinical 
studies that indicate a strong correlation be-
tween poor prognosis of the disease and high 
infiltration of macrophages in the tumor (Bingle 
et al., 2002; Knowles and Harris, 2007). For 
example, high macrophage infiltration strongly 
associates with reduced relapse-free and overall 
survival of breast cancer patients (Leek, et al., 
1996). The intensive infiltration of macrophages 
is also found in a genetically engineered mouse 
(GEM) model of breast cancer caused by the 
mammary epithelial restricted expression of 
the Polyoma Middle T oncogene (PyMT; Lin 
et al., 2001, 2003). Importantly, ablation of 
macrophages in the PyMT mice through a null 
mutation of colony-stimulating factor 1 gene 
(Csf1op/op) dramatically suppressed lung metas-
tases (Lin et al., 2001), which indicates pivotal 
roles of macrophages in breast cancer pulmo-
nary metastasis.
It has been reported that macrophages are 
diverse and contain many different populations 
that play specific roles in developmental pro-
cess, tissue repair, inflammatory responses, and 
tumor development (Pollard, 2009; Davies et al., 
2013). In mice, macrophages are characterized 
by their high expression of surface markers such 
as F4/80 and CD68, and no expression of Ly6G. 
In the lung of the PyMT mice with metastatic 
lesions, there are at least two distinct macro-
phage populations: F4/80+CD11c+ and F4/
80+CD11b+ macrophages (Qian et al., 2009). 
The F4/80+CD11c+ macrophages are alveolar 
macrophages that also exist in the normal lung. 
Although these CD11c+ resident macrophages 
are required for clearance of cellular debris and 
initiation of inflammatory responses (Hussell 
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Pulmonary metastasis of breast cancer cells is promoted by a distinct population of macro-
phages, metastasis-associated macrophages (MAMs), which originate from inflammatory 
monocytes (IMs) recruited by the CC-chemokine ligand 2 (CCL2). We demonstrate here 
that, through activation of the CCL2 receptor CCR2, the recruited MAMs secrete another 
chemokine ligand CCL3. Genetic deletion of CCL3 or its receptor CCR in macrophages 
reduces the number of lung metastasis foci, as well as the number of MAMs accumulated 
in tumor-challenged lung in mice. Adoptive transfer of WT IMs increases the reduced 
number of lung metastasis foci in Ccl3 deficient mice. Mechanistically, Ccr deficiency 
prevents MAM retention in the lung by reducing MAM–cancer cell interactions. These 
findings collectively indicate that the CCL2-triggered chemokine cascade in macrophages 
promotes metastatic seeding of breast cancer cells thereby amplifying the pathology al-
ready extant in the system. These data suggest that inhibition of CCR, the distal part of 
this signaling relay, may have a therapeutic impact in metastatic disease with lower toxic-
ity than blocking upstream targets.
© 2015 Kitamura et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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CD11b+ MAMs express a much higher level of CCR2 com-
pared with CD11c+ pulmonary resident macrophages (Qian 
et al., 2009), suggesting that MAMs receive more CCR2 
signal than resident macrophages. We therefore compared 
the gene expression profile of MAMs (F4/80+CD11b+) with 
those of resident macrophages in normal lung (Lng M; F4/
80+CD11c+) and similarly isolated splenic (Spl M; F4/
80+CD11b+) macrophages. Hierarchical clustering clearly 
separated MAMs from other resident macrophages, and iden-
tified 37 genes whose expression was significantly higher in 
MAMs (Fig. 1, A and B). To narrow down the candidates, 
we compared mRNA levels of these genes between WT and 
Ccr2-deficient macrophages and found eight genes whose 
expression was significantly reduced in Ccr2-deficient macro-
phages (Fig. 1 C). Notably, one of these genes encodes the 
CC-chemokine ligand 3 (CCL3), a high-affinity ligand for 
CCR1 (Neote et al., 1993) whose expression in myeloid cells 
is associated with metastasis of colon cancer and lymphoma 
cells (Kitamura et al., 2010; Rodero et al., 2013). It is also 
reported that CCL3 enhances intracellular calcium flux in 
human macrophages but not monocytes (Kaufmann et al., 
2001), suggesting that CCL3 might possess specific roles in 
macrophage functions. We thus hypothesized that activation 
of CCL2–CCR2 signaling prompts macrophages to secrete 
CCL3, which regulates prometastatic functions of MAMs.
Consistent with the results from the microarray and real-
time PCR, we found 40–50% reduction in CCL3 protein 
secretion from Ccr2-deficient macrophages compared with 
that from WT macrophages (Fig. 2, A and B). In the WT 
macrophages, stimulation with recombinant CCL2 significantly 
increased CCL3 mRNA and protein expression (Fig. 2 B). 
Because such an increase in CCL3 secretion was not found in 
Ccr2-deficient macrophages (Fig. 2 B), these results indicate 
that CCL2 signaling via CCR2 can increase CCL3 secretion 
from macrophages. Recombinant CCL2 failed to increase 
CCL3 secretion in Ccr2/ BMDMs, and thus it is unlikely 
that any increase in CCL3 secretion is induced by contami-
nating endotoxin. Indeed, endotoxin contamination is reported 
as <0.01 ng/ml in our culture conditions and this is much less 
than is needed to increase CCL3 secretion from alveolar and 
peritoneal macrophages (Wang et al., 2000). To investigate 
whether CCL2 promotes Ccl3 expression in MAMs in vivo, 
we injected anti-CCL2 neutralizing antibody into WT mice 
having a similar load of lung metastases. After 2 d of antibody 
treatment, we isolated MAMs (F4/80+CD11b+CD11c–Ly6C–) 
and resident pulmonary macrophages (F4/80+CD11b–CD11c+ 
Ly6C–) from tumor-bearing lung and inflammatory mono-
cytes (IM; CD115+CD11b+Ly6C+) and resident monocytes 
(RM; CD115+CD11b+Ly6C–) from peripheral blood (Fig. S1). 
The treatment with anti-CCL2 antibody significantly sup-
pressed Ccl3 transcript levels in MAMs (Fig. 2 C), indicating 
that CCL2 can increase CCL3 expression in macrophages at 
the metastasis sites as well. Interestingly, MAMs expressed 
10-fold higher Ccl3 mRNA compared with either circu-
lating IMs or RMs, or resident macrophages in the lung. 
It is notable that other major leukocyte populations in the 
and Bell, 2014), they are not involved in breast cancer metastasis 
(Qian et al., 2009). In contrast, the CD11b+ macrophages are 
recruited by metastasizing cancer cells but are few in number in 
normal lung. In an experimental metastasis model of breast 
cancer, these CD11b+ macrophages are recruited and in direct 
contact with disseminating cancer cells within 48 h after tumor 
injection, which promotes extravasation of cancer cells. Be-
cause depletion of the CD11b+ macrophages reduces the num-
ber and size of metastatic foci in the lung (Qian et al., 2009), 
the recruitment of these metastasis-associated macrophages 
(MAMs) is essential for extravasation and persistent growth of 
breast cancer cells.
We have recently reported that adoptively transferred in-
flammatory monocytes (IMs) characterized as CD11b+Ly6Chigh 
preferentially migrate to the lung with metastatic tumors than 
the primary tumor (Qian et al., 2011). We have also found that 
treatment with antibodies against the CC-chemokine ligand 2 
(CCL2) suppresses the recruitment of IMs and reduces the 
number of MAMs in the lung, indicating that MAMs originate 
from circulating IMs. Because IMs express the CCL2 receptor 
CCR2 at high levels and anti-CCL2 antibody treatments re-
duce the number of metastatic foci, the CCL2–CCR2 axis plays 
an important role in metastatic seeding of breast cancer cells via 
recruitment of IMs. Our results thus suggest CCL2 as a potential 
therapeutic target to prevent the MAM-mediated tumor metas-
tasis. However, anti-CCL2 antibody is ineffective at suppress-
ing free CCL2 in humans (Sandu et al., 2013). Moreover, loss 
of CCL2 signaling severely depresses numbers of circulating 
monocytes that increases susceptibility to infection in mouse 
models (Serbina et al., 2008), suggesting the requirement for 
alternative targets to suppress prometastatic function of MAMs.
Although CCL2 is known as a monocyte chemoattractant 
(Matsushima et al., 1989), it also promotes phagocytosis, sur-
vival, and polarization of myeloid cells (Roca et al., 2009; 
Tanaka et al., 2010). We thus hypothesized that the CCL2–
CCR2 axis may regulate functions of MAMs, and could be 
another mechanism underlying MAM-mediated metastatic 
seeding of cancer cells. Accordingly, we have found that the re-
cruited MAMs also express CCR2 (Qian et al., 2009), and loss 
of Ccr2 reduces ability of macrophages to support cancer cell 
extravasation in vitro (Qian et al., 2011). Here, we demonstrate 
a novel role of the CCL2–CCR2 axis in breast cancer metasta-
sis. We show that activation of CCR2 signaling prompts 
MAMs to secrete another chemokine, CCL3. The increased 
CCL3 secretion results in enhanced MAM–cancer cell inter-
action and prolonged retention of MAMs in the metastasis 
sites, which promotes extravasation of cancer cells. These data 
identify a novel prometastatic chemokine cascade that pro-
motes lung metastasis.
RESULTS
Activation of CCL2–CCR2 axis increases  
CCL3 secretion from MAMs
To test our hypothesis that CCR2 acts as a signaling receptor 
in MAMs, we first identified potential downstream targets of 
CCR2 signaling in the MAMs. Previously, we reported that 
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they differentiate from IMs, and it is regulated, at least in part, 
by the CCL2–CCR2 signaling pathway. Our results, how-
ever, do not exclude the contribution of other pathways in 
the regulation of CCL3 synthesis.
CCL3 secretion from MAMs promotes  
metastatic seeding of breast cancer cells
Although the role of CCL3 in breast cancer metastasis re-
mains unclear, oncomine search results (Farmer et al., 2005; 
Finak et al., 2008) indicated that CCL3 was up-regulated in 
breast cancer stroma and in basal-like invasive breast carci-
noma that are predicted to have poor prognoses (Fig. 3 A). 
These results suggest that stromal expression of CCL3 is 
involved in breast cancer progression. To investigate the role 
of CCL3 in breast cancer metastasis, we injected MDA-MB-
231:4175 cells expressing luciferase (Minn et al., 2005) into 
the mammary fat pad of nude mice as a model for human 
triple negative breast cancer. The recipient nude mice were 
irradiated and transplanted with BM cells from immunodefi-
cient mice (Rag2/) or those that are homozygous for the 
Ccl3-null allele (Rag2/Ccl3/) before tumor implantation 
so that we could investigate the role of CCL3 from BM cells. 
4 wk after tumor injection, we resected the primary tumor 
tumor-bearing lung expressed low levels of Ccl3 mRNA 
comparable with resident macrophages, suggesting MAMs 
are the major source of CCL3 in the metastasis site (Fig. 2 D). 
Consistent with these data, CCL3 mRNA level in human 
monocyte-derived macrophages (hMDMs) was significantly 
higher than freshly isolated monocytes, and this level was in-
creased by recombinant human CCL2 (Fig. 2, E and F). We 
have reported that CCL3 secretion from cultured macro-
phages is increased by conditioned medium from mouse 
mammary tumor cells (Ojalvo et al., 2009). Likewise, condi-
tioned medium from various subtypes of human breast can-
cer cells increased CCL3 levels in hMDMs (Fig. 2 G). The 
conditioned medium contained CCL2 (MDA435, 56.5 ± 
3.7; MDA231, 37.8 ± 5.2; T47D, 13.0 ± 0.6; MCF7, 59.4 ± 
3.5 pg/ml), and the increase in CCL3 by the conditioned 
medium from MDA231 cells that induced highest amount of 
CCL3 was suppressed by anti-human CCL2 antibody treat-
ment (67% compared with control IgG treatment; Fig. 2 H). 
The anti-CCL2 antibody treatment also suppressed CCL3 
expression induced by conditioned medium from MDA435 
(78% compared with control IgG treatment) but not from 
T47D and MCF7 cells (unpublished data). Collectively, these 
results indicate that MAMs secrete high level of CCL3 once 
Figure . Identification of MAM-specific 
genes regulated by CCR2 signaling in 
mice. (A) Heat maps of unsupervised hierar-
chical clustering of microarray analysis of 
RNA isolated from MAMs (F4/80+CD11b+) 
compared with those from resident lung mac-
rophages (Lng; F4/80+CD11c+) and splenic 
macrophages (Spl; F4/80+CD11b+). MAMs 
were isolated from mice injected with Met-1 
mouse breast cancer cells (n = 3/group).  
Color bars show intensity of gene expression. 
(B) Genes differentially regulated in MAMs 
(more than threefold change; P < 0.01, 
ANOVA) were clustered according to GO 
terms. Data on expression values are pre-
sented as means ± SEM. Note that the scale is 
exponential. (A and B) data were derived from 
three independent repeats for each sample 
group. (C) The relative mRNA expression of 
candidate genes (as indicated) was assessed 
by RT-PCR in BMDMs isolated from WT or 
Ccr2/ mice (n = 3, three independent ex-
periments). Data are means ± SEM. *, P < 0.05.
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PyMT:Ccl3+/+ mice (Fig. 3, C and D). As we could not find 
significant differences in the size of foci or weight of primary 
tumors (Fig. 3 D), CCL3 appears to be required for metastatic 
seeding of cancer cells rather than their growth at the primary 
and metastatic sites.
We thus investigated the role of CCL3 in extravasa-
tion, one of the rate-limiting steps of metastasis, using an 
experimental metastasis model that enables cancer cells to 
and determined tumor loads in the lung by in vivo biolumi-
nescence imaging. In support of our hypothesis, the sponta-
neous pulmonary metastases from the orthotopic 4175 tumors 
were markedly suppressed by Ccl3 deficiency (Fig. 3 B). To 
confirm this result in a spontaneous tumor-developing GEM 
model, we introduced the Ccl3-null allele to the PyMT mice 
on a BL6 background and found that the number of lung 
metastasis foci was significantly lower in PyMT:Ccl3/ than 
Figure 2. CCR2 signaling regulates CCL3 expression in MAMs. (A) Levels of Ccl3 mRNA (left) and CCL3 protein (right) in BMDMs isolated from WT 
or Ccr2/ mice were assessed by RT-PCR (n = 6 per genotype, 6 independent experiments) and ELISA (n = 3 per genotype, two independent experi-
ments). Data are means ± SEM. *, P < 0.01 versus WT. (B) Ccl3 mRNA (left) and CCL3 protein (right) were assessed by RT-PCR (n = 3, 2 independent ex-
periments) and ELISA (n = 3 per genotype, 2 independent experiments) in macrophages cultured with PBS or recombinant CCL2 (100 ng/ml). The BMDMs 
were isolated from WT or Ccr2/ mice. Data are means ± SEM. *, P < 0.01. (C) Expression of Ccl3 mRNA was assessed by RT-PCR (n = 4, four independent 
experiments) in monocytes and macrophages obtained from E0771-LG tumor-injected mice treated with neutralizing anti-CCL2 or control IgG antibodies. 
IM, inflammatory monocytes (CD115+CD11b+Ly6C+); RM, resident monocytes (CD115+CD11b+Ly6C–); MAMs (F4/80+CD11b+CD11c–Ly6C–); Rmac, resident 
macrophages (F4/80+CD11b–CD11c+Ly6C–). Data are means ± SEM. *, P < 0.01 versus IgG-IM; †, P < 0.05 versus IgG-MAM. Gating strategies are shown 
Fig. S1. (D) Expression of Ccl3 mRNA was assessed by RT-PCR in Rmac, MAM (n = 7, 7 independent experiments) or neutrophil (Neu), CD4+ T cell, CD8+  
T cell, B cell, and NK cell (n = 3, 3 independent experiments). The leukocytes were isolated from tumor-bearing mouse lung. Data are means ± SEM. *, P < 
0.01 versus Rmac. (E) Relative CCL3 mRNA expression was assessed by RT-PCR (n = 4, 4 independent experiments) in human monocytes (Mo) and those 
differentiated into macrophages by CSF-1 (Mac). Data are means ± SEM. *, P < 0.05. (F) Relative CCL3 mRNA level was assessed by RT-PCR (n = 4, 4 inde-
pendent experiments) in human macrophages cultured with recombinant human CCL2 (100 ng/ml). Data are means ± SEM. *, P < 0.05. (G) Expression of 
CCL3 mRNA was assessed by RT-PCR in human MDMs (hMDM) cultured with conditioned medium (C.M.) from human cancer cell lines as indicated. As a 
control (–), the cells were cultured in nonconditioned medium (MEM including 10% FBS and 103 U/ml CSF-1). n = 5, 5 independent experiments. Data 
are means ± SEM. *, P < 0.01. (H) Expression of CCL3 mRNA was assessed by RT-PCR in human macrophages cultured in MDA231 conditioned medium 
with neutralizing anti-CCL2 or control IgG antibodies. n = 3. Data are means ± SEM. *, P < 0.05.
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complete neutralization of CCL3 in mice that is greater than 
the amount of antibody available to us for this experiment. 
Nevertheless the effects were highly significant compared with 
the control antibody.
To investigate the contribution of MAMs to this CCL3-
promoting metastasis, we performed adoptive transfer of IMs. 
We have reported that transferred IMs (CD11b+Ly6Chigh) are 
readily detectable in the tumor-challenged lung at least 5 d 
after transfer, and a significant portion of them have differen-
tiated into MAMs (CD11b+Ly6Clo) within 2 d (Qian et al., 
2011). We have also shown that intravenously injected can-
cer cells extravasate within 2 d after injection and this seeding 
is suppressed by macrophage depletion (Qian et al., 2009), 
suggesting that IMs injected with cancer cells can differenti-
ate to MAMs and support tumor metastasis. We thus injected 
IMs isolated from WT (Ccl3+/+) or Ccl3/ mice in combi-
nation with cancer cells to the mice transplanted with Ccl3/ 
BM cells (BMT:Ccl3/). Importantly, the suppressive effect 
on foci numbers in the BMT:Ccl3/ mice was significantly 
rescued by the one-time injection of Ccl3+/+ IMs (Fig. 4 C). 
In contrast, adoptive transfer of Ccl3/ IMs did not change 
the number of foci. Because MAMs originate from IMs (Qian 
avoid the early metastatic steps from the primary tumor such 
as local invasion and intravasation. Namely, we injected 
E0771-LG cells into the tail vein of mice that received BM 
transplantation (BMT) from WT, Ccl3/, or Ccr2/ mice. 
Consistent with our other experimental models, transplanta-
tion of Ccl3/ BM cells reduced number of foci without 
affecting the size of foci (Fig. 4 A). The suppressive effect of 
Ccl3 gene ablation was comparable with that of Ccr2 knockout. 
To investigate the requirement of CCL3 in lung metastasis 
of another cell line, we performed experimental metastasis 
assays with Met-1 mouse mammary tumor cells. Because 
the cells are derived from the PyMT tumor in FVB mice 
(Borowsky et al., 2005), we used anti-CCL3 neutralizing an-
tibody instead of Ccl3/ mice (C57BL/6). Consistent with 
the genetic model, pretreatment with anti-CCL3 antibody 
significantly suppressed the number of foci (Fig. 4 B). Al-
though the suppressive effect of the antibody treatment was 
smaller than that of genetic Ccl3 deletion, we are unable to 
compare the two models (Met-1 and E0771) in the null mutant 
because of the genetic background. The lower effect caused 
by the antibody treatment may also due to the very high dose 
of the antibody (ND50 = 5–25 µg/ml) required to achieve 
Figure 3. Loss of CCL3 in stromal cells suppresses pulmonary metastasis of human and mouse breast cancer cells. (A) Oncomine search results 
for CCL3 are shown. (left) CCL3 transcript abundance in stroma of breast cancer (Ca) and normal tissue (N). P = 2.61 3 10-16; fold change, 3.078. (right) 
CCL3 levels in basal-like (Bs) and luminal-like (Lm) invasive breast carcinoma showing increase in basal cancers. P = 2.28 3 10-4; fold change, 1.747. 
(B) Lung metastatic burden from orthotopic mammary tumors was quantified (n = 3/genotype, 3 independent experiments). The tumors were developed 
by MDA231:4175TGL human breast cancer cells in nude mice transplanted with Rag2/ or Ccl3/Rag2/ BM cells. Plots show normalized photon flux 
in the lung over time. Data are means ± SEM. *, P < 0.05. Representative images of mice at 35 wk are shown (right). (C) Representative H&E stained mi-
croscopy images of the lung from PyMT (n = 8) and PyMT:Ccl3/ (n = 7) mice with spontaneous metastatic foci (Arrowheads) are shown. Bars, 1 mm.  
(D) Number and size of lung metastatic foci (left) and primary tumor weights (right) were assessed in autochthonous PyMT (n = 8) or PyMT:Ccl3/ mice 
(n = 7) at 27–30 wk of age (4 independent experiments). Data are means ± SEM. *, P < 0.01.
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cells. Supporting this interpretation, in vitro extravasation of 
cancer cells, which was promoted by WT macrophages, was 
significantly suppressed by Ccl3 deficiency (Fig. 4 D). It is 
et al., 2011) and are the major source of CCL3 in the metastasis 
sites (Fig. 2 D), these results collectively indicate that CCL3 
from MAMs can promote metastatic seeding of breast cancer 
Figure . Expression of CCL3 in MAMs promotes metastatic seeding of cancer cells. (A) Number and size of lung foci were assessed in WT irradi-
ated mice transplanted with BM cells from C57BL/6 (WT, n = 13), Ccl3/ (n = 14), or Ccr2/ (n = 15) mice (three independent experiments). After recon-
stitution of their BM, mice were injected with E0771-LG cells and euthanized after 11 d. Data are means ± SEM. *, P < 0.01 versus WT. (B) Number and 
size of lung foci were assessed in FVB mice injected with Met-1 cells (three independent experiments). Mice were treated with IgG (n = 9) or anti-CCL3 
antibodies (n = 6) 24 and 2 h before tumor injection. Data are means ± SEM. *, P < 0.01. (C) Number and size of lung foci were assessed at day 11 after 
E0771-LG tumor cell injection in mice transplanted with WT (n = 8) or Ccl3/ (n = 7) BM. The Ccl3/ BM transplanted mice were also injected with WT 
(Ccl3+/+, n = 7) or Ccl3/ (n = 6) inflammatory monocytes (IMs). Data are means ± SEM from four independent experiments. *, P < 0.01 versus WT; †, P < 
0.05 versus Ccl3/. (D) Number of transmigrated E0771-LG cells was measured in the transendothelial migration assay in the absence (–) or presence of 
BMDMs from C57BL/6 or Ccl3/ mice (n = 3, 2 independent experiments). Mean cell number in each insert was determined by the counts from five 
fields. Data are means ± SEM. *, P < 0.05 versus BMM (–); †, P < 0.01 versus WT. (E) mRNA expression of CC-chemokine ligands and their receptors in 
cultured mouse macrophages (BMDM), cancer cells (Met-1 and E0771), and endothelial cells (3B-11), as indicated (two independent experiments). 
PCR product size (bp) is shown on the right. (F) Secretion of CCL3 protein was assessed by ELISA in cultured mouse macrophages (BMDM), cancer cells  
(Met-1 and E0771), and endothelial cells (3B-11), as indicated (n = 3, three independent experiments). ND, not detected. (G) mRNA expression of  
CCL3 and its receptors in cultured human macrophages (MDM) and breast cancer cell lines (two independent experiments). PCR product size (bp) is 
shown on the right.
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circulating IMs (Fig. 5 E) and reduced the number of metastatic 
foci (Fig. 5 F). As a control administration of Dox alone did 
not affect the number of metastasis foci (Control, 0.41 ± 0.1; 
Dox treated, 0.52 ± 0.2/mm2 lung area), these results indi-
cate that CCL3 promotes metastatic seeding of cancer cells 
by promoting the early accumulation of IM/MAMs.
CCR1 and CCR5 are the only known cognate receptors 
of CCL3 (Schall and Proudfoot, 2011). To determine their 
contributions to the early MAM accumulation, we first con-
firmed that MAMs expressed CCR1 and CCR5 (Fig. 6 A). 
Interestingly, MAMs expressed higher levels of Ccr1 and Ccr5 
mRNA and protein than circulating IMs (Fig. 6, A and B). 
In contrast, CCR2 is expressed higher on IMs than MAMs 
(Fig. 6 A). Consistent with our in vitro data (Fig. 4 E), CD45– 
CD31+ endothelial cells in the tumor-challenged lung or 
E0771 cancer cells did not express CCR1 or CCR5 (Fig. 6, 
C and D). Next we determined the number of CD11b+ 
macrophages in the lungs of WT, Ccr1/, or Ccr5/ mice 
24 h after tumor-cell injection. Consistent with our previous 
results (Qian et al., 2009; Fig. 5 A), tumor-injected WT mice 
showed 70% increase in number of MAMs compared with 
normal mice. Such increase was significantly reduced in 
Ccr1/ mice whereas the number of IMs were not changed 
(Fig. 6 E). In contrast, loss of Ccr5 did not suppress the MAM 
accumulation (Fig. 6 E), suggesting that it is the CCL3–
CCR1 axis that is required for early accumulation of MAMs. 
Loss of Ccr1 also suppressed the number of metastatic foci and 
the ability of macrophages to promote in vitro extravasation 
of breast cancer cells (Fig. 6, F and G). In the in vitro extrava-
sation assay, macrophages are the only cell type that expresses 
CCR1 and it is not expressed by cancer (E0771 or Met-1) or 
endothelial (3B-11) cells (Fig. 6, D and H). Collectively, 
these results show that the MAM-derived CCL3 mainly acts 
as an autocrine mediator and that the MAM accumulation 
through CCL3–CCR1 axis is involved in promotion of can-
cer cell extravasation.
CCR signaling prolongs retention of MAMs at metastasis 
sites by enhancing MAM-cancer cell interaction
To investigate how CCR1 promotes MAM accumulation, 
we injected WT or Ccr1/ IMs labeled with CMFDA fluor-
escent dye into mice bearing similar lung metastatic loads 
and followed their fate up to 42 h after transfer. Labeled 
monocytes from both genotypes infiltrated into the lung to a 
similar extent after 18 h. By 42 h, however, there were sig-
nificantly fewer Ccr1/ cells than WT cells (Fig. 7 A). While 
the ratio of CMFDA+ cells in the MAM population, which 
indicates differentiation of IMs (CD11b+Ly6c+) to MAMs 
(CD11b+Ly6c–), increased by 42 h, there was no difference 
between WT and Ccr1/ mice (Fig. 7 B). These results in-
dicate that activation of CCR1 signaling promotes retention 
of MAMs in the metastatic lung, but not the recruitment or 
differentiation of IMs.
Because most cancer cells extravasate within 48 h after 
injection and interact with MAMs in the lung (Qian et al., 
2009), we hypothesized that the CCL3–CCR1 axis might 
noteworthy that only the macrophages expressed Ccr2 and 
Ccl3 in this in vitro system (Fig. 4, E–G), suggesting that 
macrophages are the cells that respond to CCL2 signaling and 
produce CCL3.
CCL3–CCR axis enhances MAM accumulation  
and promotes tumor metastasis
Because mRNA of the CCL3 receptors CCR1 and CCR5 
are expressed predominantly by human and mouse macro-
phages rather than breast cancer cells or endothelial cells (Fig. 4, 
E–G; see also Fig. 6 H), the MAM-derived CCL3 is likely to 
act as an autocrine mediator for MAMs rather than increasing 
cancer cell motility/invasiveness or vascular permeability. In 
the experimental metastasis model, we have shown that the 
MAMs (CD11b+) are recruited to the lung as early as 36 h 
after introduction of cancer cells into circulation. Using an 
ex vivo imaging system, we have also shown that majority of 
the i.v. injected cancer cells directly contact with the MAMs 
and extravasate within 48 h. In this system, macrophage deple-
tion markedly delays the tumor cell extravasation (Qian et al., 
2009). We therefore hypothesized that MAM-derived CCL3 
may promote metastatic seeding by enhancing the early ac-
cumulation of MAMs in tumor cell challenged lungs. To test 
this hypothesis, we determined the number of CD11b+ mac-
rophages in the lung from WT or Ccl3/ mice 24 h after 
tumor injection. Consistent with our previous results (Qian 
et al., 2009), the number of CD11b+ macrophages was very 
low in the normal lung of WT mice and was increased by 
tumor injection by 24 h (Fig. 5 A and Fig. S1). However, 
such an accumulation did not occur in Ccl3/ mice (Fig. 5 A), 
suggesting that CCL3 is required for MAMs to accumulate 
at the metastasis sites. Although Ccr2 deficiency suppressed 
MAM accumulation, it also suppressed basal levels of CD11b-
positive cells and circulating monocytes (Fig. 5 A), consistent 
with the role for the CCL2–CCR2 axis regulating monocyte 
emigration from the BM (Serbina et al., 2008). In contrast, 
loss of Ccl3 did not alter the steady-state numbers of MAMs 
or monocytes (Fig. 5 A). Furthermore, Ccl3 deficiency did 
not reduce the numbers of resident macrophages, neutro-
phils, or lymphocytes (Fig. 5 B). Although tumor injection 
increased neutrophil accumulation in the lung of WT mice, 
this was independent of CCL3. Nevertheless, we investigated 
whether there is a contribution of neutrophils to metastatic 
seeding by depleting them via anti-Ly6G antibodies treat-
ments (Fig. 5 C). To deplete neutrophils during metastatic 
seeding, we treated mice with antibodies 24 and 5 h before, 
and 16 h after tumor injection, as most i.v. injected cancer 
cells complete extravasation within 48 h (Qian et al., 2009) 
and the suppressive effect of a single antibody injection lasts 
at least 2 d (Cain et al., 2011). We found that the anti-Ly6G 
depletion of neutrophils did not alter the numbers of lung 
metastatic foci (Fig. 5 D). In contrast, depletion of the MAM 
progenitor IMs significantly suppressed lung metastasis of 
cancer cells (Fig. 5, E and F). To establish this, we used rtTA:
tetO-Cre:Csf1rF/F mice treated with doxycycline (Dox), in 
which loss of functional CSF-1 receptor significantly ablated 
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C and D). We then determined the duration of interaction 
between macrophages and E0771-LG cancer cells in vitro. 
We cultured macrophages labeled with CMTMR fluor-
escent dye on Matrigel with cancer cells and tracked them for 
enhance MAM retention through regulating the interaction 
between cancer cells and MAMs. Supporting this hypothesis, 
loss of Ccl3 or Ccr1 reduced the numbers of CD11b+ cells 
interacting with disseminating cancer cells in the lung (Fig. 7, 
Figure . CCL3 is required for MAMs to accumulate in tumor-challenged lung. (A) Relative numbers of lung CD11b+ macrophages (left) or circu-
lating CD11b+CD115+ monocytes (right) in C57BL/6 (WT; n = 14), Ccl3/ (n = 4), and Ccr2/ (n = 4) mice (normal; N) were compared with those i.v. 
injected with E0771-LG cells 24 h before measurement (tumor; T). IM, inflammatory monocytes (Ly6C+); RM, resident monocytes (Ly6C–). Data are mea-
sured as percentage of macrophages or monocytes in CD45+ cells (at least four independent experiments). Data are means ± SEM. *, P < 0.05 versus 
WT-N; †, P < 0.05 versus WT-T. Gating strategy is shown in Fig. S1. (B) Relative numbers of leukocytes in lungs of C57BL/6 (WT; n = 14), Ccl3/ (n = 4), 
and Ccr2/ (n = 4) mice are shown. Mice were injected with PBS (Normal) or E0771-LG cells (Tumor) 24 h before measurement. Rmac, resident macro-
phages; Neu, neutrophils. Data are measured as percentage of macrophages or monocytes in CD45+ cells (at least four independent experiments) and 
shown as means ± SEM. *, P < 0.05 versus WT-Normal. (C) Relative numbers of circulating neutrophils (Neu) and inflammatory monocytes (IM) in WT 
mice 24 h after 2 d of treatment with anti-Ly6G antibody (n = 5, two independent experiments). Data are measured as percentage of macrophages  
or monocytes in CD45+ cells. Data are means ± SEM. *, P < 0.01. (D) Number of lung foci was assessed in neutrophil depleted WT mice at day 11 after 
E0771-LG breast cancer cell injection. Mice were treated with IgG or anti-Ly6G antibodies 24 or 5 h before, and 16 h after tumor cell injection (n = 4, four 
independent experiments). Data are means ± SEM. No statistical significance was observed. (E) Relative number of circulating monocytes was assessed in 
rtTA:tetO-Cre:Csf1rF/F mice treated with or without doxycycline (Dox) in drinking water for 7 d (n = 4, 2 independent experiments). Data are means ± SEM. 
*, P < 0.01. (F) Number of metastasis foci was assessed in monocyte-depleted rtTA:tetO-Cre:Csf1rF/F mice at day 11 post-tumor injection. The rtTA:tetO-
Cre:Csf1rF/F mice injected with E0771-LG cells were given water with or without doxycycline (Dox) in drinking water from 7 d before tumor injection to 
the endpoint (n = 7, 2 independent experiments). Data are means ± SEM. *, P < 0.01.
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Figure . The CCL3–CCR axis is required for accumulation of MAMs and after extravasation of cancer cells. (A) Levels of chemokine 
receptors were assessed by flow cytometry in circulating inflammatory monocytes (IMs) and lung MAMs, as indicated. Cells were isolated from WT 
mice 24 h after E0771-LG tumor cell injection (n = 3). Dotted lines and shaded areas show control isotype matched IgG for each cell type. Repre-
sentative histograms from three independent experiments are shown. (B) Levels of Ccr1 and Ccr5 mRNA were assessed in IMs, MAMs, and E0771-
LG cancer cells. Cells were isolated from WT mice 24 h after E0771-LG tumor cell injection (n = 4). Data are means ± SEM. *, P < 0.05 versus IM.  
(C) Levels of chemokine receptors were assessed in CD45CD31+ endothelial cells from the tumor cell–challenged lung. Cells were isolated from 
WT mice 24 h after E0771-LG tumor cell injection (n = 3). Dotted lines and shaded area show control isotype matched IgG for each receptor. A rep-
resentative histogram from two independent experiments is shown. (D) Levels of chemokine receptors on cultured E0771-LG tumor cells were 
assessed by flow cytometry. Dotted lines and shaded areas show control isotype matched IgG for each receptor. A representative histogram from 
two independent experiments is shown (n = 2). (E) Relative numbers of lung CD11b+ macrophages (top) and circulating CD11b+CD115+ monocytes 
(bottom) were assessed by flow cytometry in C57BL/6 (WT; n = 14), Ccl3/ (n = 4), Ccr1/ (n = 7), and Ccr5/ (n = 7) mice challenged with 
E0771-LG cells 24 h before measurement (at least two independent experiments/genotype). Data are means ± SEM. *, P < 0.05 versus WT. (F) Number 
and size of lung foci were assessed in mice transplanted with BM cells from C57BL/6 (WT, n = 14), Ccl3/ (n = 11), or Ccr1/ (n = 9) mice. Mice 
were injected with E0771-LG cells (two independent experiments). Data are means ± SEM. *, P < 0.01. (G) Number of transmigrated E0771-LG cells 
was measured in the transendothelial migration assay in the presence of BMDMs from C57BL/6 or Ccr1/ mice (n = 6, three independent experi-
ments). Mean cell number in each insert was determined by the counts from five fields. Data are means ± SEM. *, P < 0.01. (H) CCR1 protein 
expression was assessed by flow cytometry in BMDMs, 3B-11 endothlial cells, and Met-1 tumor cells. A representative histogram from two inde-
pendent experiments is shown (n = 2).
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Figure 7. CCR signaling enhances at-
tachment of macrophages to cancer cells 
and promotes their retention in tumor-
bearing lung. (A) The fate of transferred 
CMFDA-labeled IMs in mouse lung metasta-
ses were followed. CD11b+CD115+Ly6C+ 
inflammatory monocytes (IMs) isolated from 
WT or Ccr1/ mice were labeled with 
CMFDA and transferred to WT mice that 
received i.v. injection of E0771-LG cells ex-
pressing luciferase. Pulmonary tumor bur-
dens in the recipients were determined by  
in vivo bioluminescence imaging 1 d before 
monocyte transfer (10 d after tumor injec-
tion). Relative numbers of CMFDA-labeled 
cells in CD45+CD11b+ cells from tumor bear-
ing lungs were assessed 18 or 42 h after IM 
transfer (n = 4, 4 independent experiments). 
Data are means ± SEM. *, P < 0.01. (B) Data 
show percentage of F4/80+CD11b+Ly6C 
cells (MAMs) in CMFDA+ cells from tumor 
bearing lung (n = 4, 4 independent experi-
ments). Data are means ± SEM. *, P < 0.01 
versus 18 h. n.s., not significant. (C) Number 
of CD11b+ cells associated with cancer cells 
in the lung were counted in WT Ccl3/, and 
Ccr1/ mice from images in D (n = 4, 4 
independent experiments). Interaction be-
tween cancer cells and CD11b+ myeloid cells 
were detected by immunostaining 24 h after 
intravenous injection of CMFDA-labeled 
E0771-LG cells. Data are means ± SEM.  
*, P < 0.05. (D) Representative fluorescence 
microscopy images of lung 24 h after 
E0771-LG injection. Green, CMFDA-labeled 
E0771-LG cells; Red, CD11b; Blue, nuclei; 
Arrow head, interaction between myeloid 
cells and cancer cells. Dotted line indicates 
the interaction between macrophage and 
tumor cell. Bars, 10 µm. (E) Interactions 
between macrophages and cancer cells  
(n = 3, 3 independent experiments) were as-
sessed by time-lapse imaging. Representa-
tive microscopy images over a 400-min time 
course are shown. The time when the target 
macrophage attached to cancer cells was 
designated as 0 min. Arrow head, the target 
macrophage (M) attached to the cancer cell (Ca); Red line, track of macrophage. Bars, 10 µm. See Videos 1 and 2. (F) Mean duration of inter-
actions between macrophages and cancer cells (n = 3, three independent experiments) were assessed from images in (E; 10 fields/group in each  
experiment). Data are means ± SEM. *, P < 0.01. (G) Interactions between macrophages and cancer cells were assessed by flow cytometry (n = 4,  
4 independent experiments). BMDMs from C57BL/6, Ccl3/, and Ccr1/ mice were labeled with CMTMR and mixed with CMFDA-labeled E0771-LG 
cells. Data are represented as the ratio of CMFTMR/CMFDA double-positive population. Data are means ± SEM. *, P < 0.05. (H) Surface levels of 
VCAM-1 on E0771-LG tumor cells and integrin 4 on MAMs isolated from lungs 24 h after tumor injection were assessed by flow cytometry. Repre-
sentative results from two independent experiments (n = 2) are shown. (I) Interactions between macrophages and cancer cells in the presence of 
recombinant CCL3 or PBS were assessed by flow cytometry (n = 4, four independent experiments). Macrophages were pretreated with anti-integrin 
4 neutralizing antibody (4 Ab: +) or control isotype matched IgG (4 Ab: –). Data are means ± SEM. *, P < 0.01 versus PBS; †, P < 0.05 versus 
CCL3. (J) The effect of integrin 4 inhibition on the fate of transferred IMs in mouse lung metastases was assessed by flow cytometry following the 
experimental procedure in A. Anti-integrin 4 neutralizing antibody (4) was injected 18 h after IM transfer. Relative numbers of CMFDA-labeled 
cells in CD45+CD11b+ cells from tumor bearing lung were assessed 42 h after IM transfer (n = 5, five independent experiments). Data are means ± 
SEM. *, P < 0.05.
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the pathology already in the system by promoting retention 
of recruited monocytes that stimulate tumor cell establishment 
at the metastatic site.
Our in vivo and in vitro results indicate that CCL2 can 
increase CCL3 expression in MAMs at the metastasis site. 
The CCL2-induced CCL3 expression is likely to be specific 
to the prometastatic macrophage lineage, as neutralization of 
CCL2 by antibodies significantly reduced Ccl3 expression in 
IMs and MAMs, but not in resident monocytes or macro-
phages. Consistent with this interpretation, expression of Ccl3 
was highest in MAMs compared with other leukocytes in the 
tumor-bearing lung. Importantly, a single injection of Ccl3+/+ 
IMs but not IMs lacking CCL3 was sufficient to rescue the 
suppressive effect of Ccl3/ on experimental metastasis. 
Furthermore, in our in vitro extravasation assay, macrophages 
but not cancer cells or endothelial cells secrete CCL3 protein. 
These findings strongly suggest that MAMs are the main cell 
type in the metastasis site that produces CCL3 in response to 
CCL2 signaling. In cultured macrophages, basal CCL3 secre-
tion is suppressed by Ccr2 deficiency, suggesting that CCL2 
from macrophages cell autonomously regulates their CCL3 
expression. Furthermore, CCL3 expression is increased by 
conditioned medium from cancer cells in part through a 
CCL2-mediated mechanism. These results suggest that CCL2 
secreted by both cancer cells and macrophages can promote 
secretion of CCL3 that is required for tumor metastasis. Con-
sistent with this, we have reported that both cancer cells 
and macrophages express Ccl2 mRNA, and that CCL2 from 
both tumor cells and stromal cells contribute to metastatic 
seeding of cancer cells (Qian et al., 2011). Our results, how-
ever, do not exclude the involvement of other factors in reg-
ulation of CCL3 secretion. However, identification of such 
molecules is beyond a scope of this study and requires further 
experimentation.
A recent study demonstrates that tumor-associated mac-
rophages (TAMs) in the PyMT mammary tumors also ex-
press CCR2 and are differentiated from the IMs (Franklin 
et al., 2014). We have reported that the TAMs in the PyMT 
tumors also express high level of CCL3 (Ojalvo et al., 2009), 
suggesting that CCL2 regulates CCL3 expression in the 
TAMs as well. However, it will not affect the recruitment of 
MAMs to the lung as they originate from circulating mono-
cytes (IMs) that preferentially migrate to the lung with meta-
static tumors than to the primary mammary tumors through 
CCL2-mediated mechanism (Qian et al., 2011). Indeed, in 
the current study, we found only an inhibition of metastasis 
but no deficit in PyMT primary tumor growth in the absence 
of Ccl3. In contrast to our results, i.v. injected B16 melanoma 
cells develop more lung metastatic foci in Ccl2/ or Ccl3/ 
mice than WT mice (Nakasone et al., 2012). This discrepancy 
can be explained by a difference in the immune cell profile in 
particular cancer models. Namely, stromal loss of Ccl3 or Ccl2 
reduces numbers of antitumorigenic immune cells such as 
CD4+ T, CD8+ T, and NK cells in the lung of melanoma me-
tastasis model, but their numbers were not altered in the lung 
of our breast cancer metastasis model (Fig. 5 B). In contrast, 
24 h by microscopy. The majority of WT macrophages were 
retained at the same position once they attached to cancer cells, 
and the mean interaction time was 353 ± 21 min (Fig. 7, 
E and F). In contrast, Ccl3/ or Ccr1/ macrophages inter-
acted with cancer cells for a significantly shorter time than WT 
macrophages (252 ± 16 or 204 ± 14 min, respectively; Fig. 7 F). 
We also found that Ccl3/ or Ccr1/ macrophages more 
frequently detached from cancer cells and moved around 
the dish (Fig. 7 E and Videos 1 and 2), suggesting that the 
CCL3–CCR1 axis can enhance macrophage–cancer cell inter-
action, which arrests the macrophages. To confirm these results, 
we cultured macrophages with E0771-LG cancer cells together 
in suspension for 1 h, and determined the ratio of macrophages 
interacting with cancer cells by flow cytometry. Consistent 
with our findings (Fig. 7, E and F), we found a lower number 
of Ccl3/ or Ccr1/ macrophages bound to cancer cells 
compared with WT macrophages (Fig. 7 G).
A recent report indicates that human breast cancer cells 
expressing VCAM-1 can bind to leukocytes that express 4 
integrin, a VCAM-1 receptor (Chen et al., 2011). Because 
E0771-LG mouse breast cancer cells also expressed VCAM-1 
and MAMs accumulated in the tumor-bearing lung expressed 
4 integrin (Fig. 7 H), we investigated the possibility that the 
CCL3–CCR1 axis promotes macrophages to interact with 
cancer cells through 4 integrin. The interaction between 
macrophages and cancer cells was enhanced by CCL3 in 
Ccl3/ macrophages, and suppressed by anti-4 integrin 
antibody treatment (Fig. 7 I). The antibody treatment also 
suppressed macrophage-cancer cell interaction in the absence 
of CCL3 to the comparable level with that in the presence of 
CCL3, suggesting that 4 integrin is required for both basal 
as well as CCL3-induced macrophage attachment to cancer 
cells. Furthermore, treatment of tumor-bearing mice with 
anti-4 integrin antibody 18 h after IM transfer, a time point 
when the highest number of IMs had infiltrated into the lung 
(Fig. 7 A), resulted in significantly reduced numbers of trans-
ferred cells after 42 h (Fig. 7 J). This result indicates that 4 
integrin contributes to MAM retention in vivo.
Collectively, our results in several models of metastasis 
including spontaneous GEM ones revealed the existence of 
a chemokine cascade that promotes breast cancer metastasis. 
Activation of CCL2–CCR2 signaling promotes CCL3 secre-
tion that activates CCR1 signaling in MAMs. Activation of 
CCR1 in turn enhances interaction of MAMs with metasta-
sizing cancer cells at least in part through integrin 4. As a 
result, prolonged MAM retention enhances extravasation of 
cancer cells and therefore metastasis.
DISCUSSION
Previously, we showed that a chemokine CCL2 recruits IMs 
to metastatic sites where they differentiate to MAMs (Qian 
et al., 2011). In this study, we revealed a novel role for CCL2 
as a trigger of a prometastatic chemokine cascade involving 
CCL3 signaling via CCR1 that is required for efficient me-
tastasis. These data illustrate a signaling relay that amplifies 
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contributes to the retention of IMs/MAMs. Thus, tumor 
cells may have subverted the normal cellular physiology of 
mononuclear phagocytes during infection or repair to their 
own survival advantage.
Although some studies show that CCL3 can stimulate 
in vitro migration of cancer cells (Youngs et al., 1997; Prest 
et al., 1999), we did not find expression of Ccr1 or Ccr5 in cancer 
cells. In contrast, we found that MAMs in the metastasis sites 
express both receptors, and Ccr1/5 mRNA levels are much 
higher in the MAMs than circulating monocytes. Consistent 
with our results, freshly isolated human monocytes increase 
surface expression of CCR1 and CCR5 when they are kept 
in culture and differentiate to macrophages (Kaufmann et al., 
2001). On the other hand, CCR2 expression is reduced in 
macrophages compared with monocytes. In this system, the 
differentiated macrophages thus show stronger responses to 
CCL3 than monocytes in chemotaxis and intracellular calcium 
flux assays, whereas responses to CCL2 are the opposite. The 
differential responsiveness of monocytes and macrophages to 
distinct sets of chemokines can explain why an impaired CCL3–
CCR1 axis reduces retention of MAMs without affecting 
initial recruitment of IMs (Fig. 7 A).
Our results indicate that activation of the CCL3–CCR1 
axis prolongs retention of MAMs in the lung at least in part 
through integrin 4. We also show that activation of the 
CCL3–CCR1 axis enhances adhesion of macrophages to 
VCAM-1 expressing cancer cells via integrin 4. In myeloma 
cells, CCL3 can increase the expression of integrin 1, which 
forms a heterodimer with integrin 4 and binds to the ligands 
such as fibronectin and VCAM-1 (Oba et al., 2005). In our 
metastasis model, however, the MAMs isolated from WT 
and Ccr1/ mice expressed comparable levels of integrin 4 
and 1 mRNA and protein (unpublished data), suggesting 
that the CCL3–CCR1 axis might regulate adhesive configu-
rations of integrins rather than their expression. Similar re-
sults are reported in the in vitro T cell adhesion assay (Lloyd 
et al., 1996). Namely, CCL3 induces T cell adhesion to re-
combinant VCAM-1 that is suppressed by anti-integrin 4 
neutralizing antibody, whereas CCL3 does not alter surface 
expression of integrins. CCL3 can also increase adhesion of 
hematopoietic progenitor cells to fibronectin (Suehiro et al., 
1999). The effect of CCL3 on the progenitor cells is inhibited 
by blocking antibodies against integrins 4 and 1, although 
CCL3 does not alter integrin expression. Interestingly, when 
these progenitor cells are exposed to CCL3, the amount of 
F-actin in the cell cortex is increased within 60 s. Although the 
precise mechanism remains undefined, it is possible that the 
CCL3–CCR1 axis regulates conformational changes and/or 
clustering of integrins through the polymerization of cytoskele-
tal actin that is associated with the endodomain of integrins.
Breast cancer cells frequently metastasize to the bone and 
lung, which makes breast cancer a leading cause of cancer death. 
Unfortunately, current therapies are not sufficient to prevent it 
probably because of resistance by rapid evolution of mutation-
prone cancer cells. A newly appreciated target for therapy 
is the tumor microenvironment (Joyce and Pollard, 2009; 
recruitment of prometastatic CD11b+ MAMs is reduced by lack 
of stromal CCL2 or CCL3 in breast cancer models (Fig. 5 A; 
Qian et al., 2011) but not in the melanoma model. It remains 
to be clarified how different metastatic environments regulate 
the response of immune cells to CCL2/CCL3.
To our knowledge, this is the first report demonstrating 
the involvement of a chemokine cascade in metastasis. Although 
chemokine-induced chemokine expression is reported in 
cultured mouse dendritic cells (Fischer et al., 2001) and astro-
cytes (Luo et al., 2000), its contribution to tumor progression 
remains unknown. In our metastasis models using mouse 
and human cells, loss of CCL3 reduced early accumulation 
of MAMs in the tumor-challenged lung without affecting 
recruitments of neutrophils or lymphocytes. Interestingly, 
pulmonary infection with C. neoformans can induce CCL3 
expression, and neutralization of CCL2 significantly decreases 
its levels in the lung of infected mice (Huffnagle et al., 1997). 
In this model, neutralization of CCL3 attenuated the accu-
mulation of macrophages but not lymphocytes, suggesting that 
CCL2-induced CCL3 expression may be a common mecha-
nism for macrophages to accumulate in the lung under path-
ological situations. Our results suggest that accumulation of 
macrophages (MAMs) via CCL2-induced CCL3 is required 
for the efficient metastatic seeding of cancer cells. Although 
we also found the early recruitment of neutrophils to the 
tumor-challenged lung by CCL3-independent mechanisms, 
they play a minor role in metastatic seeding, at least in our 
model. However, our results do not exclude their contribu-
tions to the establishment of metastatic foci as we treated the 
animals with neutralizing antibodies for a short time and did 
not assess the effects of prolonged treatment. In addition, neu-
trophils may well be important in cancer models other than 
breast cancer.
CCL3 can bind to CCR1 and CCR5 with high affinity. 
In our experimental metastasis model of breast cancer, loss of 
Ccr1 but not Ccr5 reduced early accumulation of MAMs that 
was observed by 24 h after tumor cell injection. In a lung 
metastasis model of renal cancer, however, loss of Ccr5 but 
not Ccr1 reduces macrophage accumulation in the lung foci 
after 7 d of tumor cell injection (Wu et al., 2008). These dif-
ferences might suggest specialized requirement of chemokine 
receptors for macrophages to accumulate in distinct micro-
environments at different phases of metastasis, i.e., CCR1 in 
early and CCR5 in late metastatic foci. Such nonredundant 
roles of CCR1 and CCR5 in myeloid cell accumulation have 
been demonstrated in some in vivo experiments using gene-
ablated mice. For example, CCR1 but not CCR5 is required 
for macrophages to accumulate in the kidney of mice that 
have received unilateral ureteral obstruction (Eis et al., 2004). 
Furthermore, intraperitoneal CCL3 injection increases the 
number of neutrophils in the peritoneal cavity within 4 h and 
this accumulation is suppressed in Ccr1/ but not in Ccr5/ 
mice (Ramos et al., 2005). Interestingly, an in vitro migration 
assay shows that CCR1 predominantly mediates the arrest 
of monocytes under shear flow (Weber et al., 2001), which 
is consistent with our finding that CCR1 predominately 
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Einstein College of Medicine, Bronx, NY), and MDA-MB-231:4175TGL 
clone was provided by J. Massagué (Memorial Sloan-Kettering Cancer Center, 
New York, NY). All cancer cells were cultured in DMEM supplemented with 
10% (vol/vol) FBS. Mouse BM derived macrophages (BMDMs) were isolated 
as described previously (Tushinski et al., 1982) and cultured in MEM supple-
mented with 10% FBS and 104 U/ml human recombinant CSF-1. In some 
experiments, the BMDMs are cultured with recombinant mouse CCL2 
(PeproTech; endotoxin level is <0.1 ng/µg of protein) for 12 h. Human blood 
(buffy coats) was obtained from New York Blood Services under informed 
consent, which is approved by Albert Einstein College of Medicine Institu-
tional Review Board. Peripheral blood mononuclear cells (PBMCs) were iso-
lated as described previously (Cassetta et al., 2013), and monocytes were iso-
lated using the Macs Monocyte isolation kit II (Miltenyi Biotec). The isolated 
monocytes were cultured in MEM supplemented with 10% FBS and 104 U/ml 
CSF-1 for 7 d to differentiate them into macrophages. In some experiments, 
the human macrophages were cultured in MEM supplemented with 10% 
FBS and 103 U/ml human recombinant CSF-1 or the same medium that had 
been conditioned from human breast cancer cells for 24 h.
Mice. Ccr2/, Ccl3/, Ccr5/, ROSA-rtTA, and tetO-Cre mice on the 
C57BL/6 genetic background were purchased from The Jackson Labora-
tory. Ccr1/ (C57BL/6) and Rag2/ mice were purchased from Taconic. 
We obtained transgenic mice expressing PyMT oncogene under the control 
of MMTV-LTR promoter (PyMT) on the FVB background from W.J. 
Muller (McGill University, Montreal, Canada) and those backcrossed with 
C57BL/6 mice (PyMT BL6) from S.J. Gendler (Mayo Clinic, Phoenix, 
AZ). The PyMT BL6 or Rag2/ mice were further crossed with Ccl3/ 
mice to construct PyMT:Ccl3/ or Rag2/:Ccl3/ compound mutants. 
We have constructed a conditional knockout strain for CSF-1 receptor that 
is essential for survival of distinct populations of myeloid cells (Li et al., 
2006). The B6.Cg-Csf1rtm1Jwp/J (Csf1rF/F) mice were crossed with ROSA-
rtTA and tetO-Cre mice to construct rtTA:tetO-Cre:Csf1rF/F mice, in which 
inflammatory monocytes are depleted by loss of Csf1r after doxycycline treat-
ment. 7–8-wk-old female mice were used unless described specifically. All 
animals were randomly allocated by genotype. All procedures involving 
mice were conducted in accordance with National Institutes of Health regu-
lations concerning the care and use of experimental animals. Experimental 
procedures were approved by Institutional Animal Care & Use Committee 
of the Albert Einstein College of Medicine.
BMT. BM cells were isolated from C57BL/6, Ccl3/, Ccr1/, Rag2/, 
or Rag2/Ccl3/ mice. BM cells were counted in a hemocytometer and 
resuspended at 2 × 107 cells/ml in PBS. The 4-wk-old recipient mice 
(C57BL/6 or nu/nu mice) were irradiated with 9 Gy -rays and transplanted 
with 4 × 106 donor cells i.v.. The recipient mice were used for experiments 
6–8 wk later.
Experimental metastasis assay. 4 × 105 E0771-LG cells were injected 
into the tail vein of C57BL/6 or knockout mice (7-wk-old female). In cases 
where the mice had received BMT, the number of cells injected was re-
duced to 3 × 105. To deplete CSF-1–dependent myeloid cells, we gave 
doxycycline in the drinking water to the rtTA:tetO-Cre:Csf1rF/F mice from 
7 d before tumor injection to the endpoint. We also injected 106 Met-1 cells 
into the tail vein of FVB females. We euthanized the mice 11 d (E0771-LG) 
or 14 d (Met-1) after tumor cell injection, and dissected the lung to prepare 
H&E sections as described previously (Qian et al., 2011). Lung images of all 
five lobes were taken using a Zeiss SV11 microscope with a Retiga 1300 
digital camera via 2× objective lens, and analyzed using Fiji software to de-
termine the average number of metastasis nodules per mm2 of lung area. The 
average size of nodules (total nodule area [mm2]/total nodule number) is 
also determined and converted to the average diameter (mm). 106 MDA-
MB-231:4175 human breast cancer cells were injected into the mammary fat 
pad of nu/nu mice that received BM cells from Rag2/ or Rag2/Ccl3/ 
mice. After 4 wk, we dissected the primary tumor and determined tumor 
loads in the lung area by in vivo bioluminescence imaging every week.
Hanahan and Coussens, 2012) and particularly macrophages 
within it because they promote breast cancer metastasis (Qian 
and Pollard, 2010) and they are not prone to hypermutation. 
CCL2 is one target fitting this strategy as it recruits MAMs 
that promote metastasis (Qian et al., 2011). Indeed, anti-CCL2 
antibodies suppress distant metastases and improve overall 
survival in preclinical models (Lu and Kang, 2009; Qian et al., 
2011; Zhu et al., 2011). However, humanized anti-CCL2 
antibody is ineffective at achieving biological effects in hu-
mans due to a feedback mechanism that increases CCL2 
production (Sandu et al., 2013), which suggests difficulty in 
suppressing the IM recruitment by CCL2 deprivation. Fur-
thermore, loss of CCL2 signaling in mouse models severely 
depresses the numbers of circulating monocytes and increases 
susceptibility to infection (Serbina et al., 2008). A recent paper 
also suggests a risk of anti-CCL2 therapy as there is a rebound 
increase of prometastatic myeloid cells after cessation of the 
therapy that accelerates the metastatic diseases (Bonapace et al., 
2014). Here, we show that human and mouse macrophages 
secrete CCL3 through activation of CCL2 signaling. Dele-
tion of CCL3 or its receptor CCR1 in macrophages reduces 
the number of lung metastasis foci developed by human and 
mouse breast cancer cells, as well as the number of MAMs 
accumulated in tumor-challenged lung without inhibiting 
circulating monocyte number. Because the suppressive effect 
of Ccl3 gene ablation is comparable with Ccr2 knockout and 
antibody treatment inhibits metastasis (Fig. 4, A and B), these 
results suggest that inhibition of the CCL2-induced chemo-
kine cascade is effective in preventing breast cancer metastasis 
and suggests that CCR1 antagonists as a better therapeutic 
option. Supporting this proposal, recent clinical trials in rheu-
matoid arthritis indicate that CCR1 antagonists show clinical 
activity without feedback-related increases in CCR1 ligands, 
suppressive effects on monocytes, or adverse events includ-
ing increased risk of infections (Dairaghi et al., 2011; Tak 
et al., 2013).
It has been reported that CCR1 can also regulate traffick-
ing of potentially tumoricidal immune cells such as T cells 
(Schaller et al., 2008), NK cells (Bernardini et al., 2008), and 
dendritic cells (Iida et al., 2008). Although an impact of CCR1 
activation in these cells on tumor metastasis is largely un-
known, it seems to play a minor role in some types of tumors 
because prolonged treatment with CCR1 antagonists sup-
presses multiple myeloma tumor burden in the bone (Dairaghi 
et al., 2012) and colon cancer liver metastasis (Kitamura et al., 
2010). These studies, as well as our current results, suggest 
the therapeutic potential of CCR1 antagonists in metastatic 
progression of certain tumor types, including breast cancer.
MATERIALS AND METHODS
Cell lines, primary samples, and cell culture. We obtained E0771 
mouse mammary adenocarcinoma cells derived from a medullary cancer 
(Ewens et al., 2005) from E. Mihich (Rosewell Park Cancer Institute, Buf-
falo, NY). To obtain highly metastatic populations, we injected E0771 cells 
i.v. into C57BL/6 mice, and cultured the cells isolated from lung meta-
static foci (E0771-LG). Human breast cancer cells MDA-MB-435, MDA-
MB-231, T47D, and MCF7 were provided by P. Kenny and O. Giricz (Albert 
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human GAPDH, 5-CAGCCTCAAGATCATCAGCA-3 and 5-TGTG-
GTCATGAGTCCTTCCA-3; human CCL3, 5-TGCAACCAGTTCT-
CTGCATC-3 and 5-TGGCTGCTCGTCTCAAAGTA-3. Primers used 
for RT-PCR are: mouse Gapdh, 5-ACTCCACTCACGGCAAATTC-3 
and 5-CCTTCCACAATGCCAAAGTT-3 (370 bp); mouse Ccl2, 
5-CCCAATGAGTAGGCTGGAGA-3 and 5-AAAATGGATCCACA-
CCTTGC-3 (434 bp); mouse Ccl3, 5-ATGAAGGTCTCCACCACTGC-
3 and 5-CCCAGGTCTCTTTGGAGTCA-3 (279 bp); mouse Ccr1, 
5-ACTCCACTCCATGCCAAAAG-3 and 5-GCAAACACAGCAT-
GGACAAT-3 (364 bp); mouse Ccr2, 5-GGGCTCACTATGCTGC-
AAAT-3 and 5-CGAAACAGGGTGTGGAGAAT-3 (400 bp); mouse 
Ccr5, 5-ATTCTCCACACCCTGTTTCG-3 and 5-GTTCTCCTGT-
GGATCGGGTA-3 (388 bp); human GAPDH, 5-ACCCAGAAGACT-
GTGGATGG-3 and 5-CCCTGTTGCTGTAGCCAAAT-3 (421 bp); 
human CCL3, 5-ATGCAGGTCTCCACTGCTG-3 (279 bp); human 
CCR1, 5-GCAGCCTTCACTTTCCTCAC-3 and 5-AGAGGAAG-
GGGAGCCATTTA-3 (447 bp); human CCR5, 5-TAGTCATCTT-
GGGGCTGGTC-3 and 5-TGAACTTCTCCCCGACAAAG-3 (321 bp).
ELISA. Mouse BM macrophages or human breast cancer cells were cultured 
in MEM supplemented with 10% (vol/vol) FBS and 103 U/ml human re-
combinant CSF-1 for 12 or 24 h, respectively. Conditioned media were col-
lected from the cultured cells, and the levels of mouse CCL3 (MIP-1) or 
human CCL2 (MCP-1) were determined using the Mouse MIP-1  ELISA 
kit or Human CCL2 (MCP-1) ELISA kit (eBioscience), respectively. Samples 
were collected independently and analyzed by one assay.
In vitro extravasation assay. The extravasation assay was performed as de-
scribed previously (Qian et al., 2011). In brief, 2 × 104 3B-11 mouse endothe-
lial cells (American Type Culture Collection) were cultured on top of GFR 
Matrigel invasion chambers (BD Biosciences) for 2 d to make a monolayer. 
BMDMs (2 × 104) were loaded to the bottom of the chambers put into a 
plate-well with DMEM including 10%FBS and 104 U/ml CSF-1 to allow at-
tachment. E0771-LG or Met-1 cells (2 × 104) labeled with CellTracker 
CMFDA were loaded into the insert with DMEM including 0.5% FBS and 
104 U/ml CSF-1. After 36 h, the chambers were fixed with 4% paraformalde-
hyde, and cells on top were removed. Fluorescent images of 5 randomly se-
lected fields in each insert were captured with Olympus IX81 fluorescence 
microscope and numbers of cancer cells migrated through endothelial mono-
layer were counted using Fiji software.
In vitro interaction assay. BMDMs and E0771-LG cells were labeled with 
CellTracker CMTMR and CMFDA (Invitrogen), respectively. To determine 
dynamic interaction between BMDMs and cancer cells, single cell suspension 
of each cells (104) were placed on Matrigel (5 mg/ml) and cultured for 1 h 
in MEM supplemented with 10%FBS and 104U/ml CSF-1. Bright-field 
and fluorescent images (10 randomly selected fields in each well) were ac-
quired every 10 min by fluorescence microscopy (Axiovert 200). Movies of 
BMDMs were tracked in Fiji ImageJ and tracks were analyzed in Mathemat-
ica (Wolfram) to determine the duration of interaction between BMDMs 
and cancer cells. To detect BMM binding to cancer cells, single cell suspen-
sion of each labeled cells (5 × 105) were mixed in v-bottom 96-well plates 
and cultured for 1 h in MEM supplemented with 10%FBS and 104 U/ml 
CSF-1. The ratio of CMFTMR/CMFDA double-positive population was 
determined by flow cytometry. Based on a side-scattered light (SSC), we 
confirmed that >80% of double-positive fraction consists doublet of cells 
whereas <10% of single positive fraction does. To maintain binding activity 
of integrin, the cells were kept in Hepes buffer containing CaCl2 and MgCl2 
during the analysis.
Immunofluorescence staining. E0771-LG cells (106) labeled with Cell-
Tracker CMFDA (Invitrogen) were injected into the mice. After 20 h, the 
lungs were dissected and directly embedded in O.C.T. compound (Sakura 
Finetek). Sections were fixed with cold acetone, immunostained with rat 
monoclonal antibodies to CD11b (1:100; BD) followed by Alexa Fluor 546 
Antibody treatment. The mice injected with 4 × 105 E0771-LG cells re-
ceived anti–mouse CCL2 neutralizing antibody or control isotype matched 
IgG (5 mg/kg body weight) via i.p. injection on days 9 and 10 after tumor 
injection. 24 h after the last treatment, the mice were euthanized to isolate 
monocytes and macrophages. To neutralize CCL3, the FVB mice injected 
106 Met-1 cells received anti–mouse CCL3 antibody or control IgG (R&D 
Systems; 5 mg/kg body weight) via i.p. injection 2 h before and 24 h after 
tumor injection. To deplete neutrophils, anti–mouse Ly6G neutralizing an-
tibodies or control isotype matched IgG (BioLegend) were given at 1 mg/kg 
body weight via i.p. injection before 24 and 5 h, and after 16 h of 
tumor injection.
In vivo bioluminescence imaging. We injected 100 µl of d-luciferin so-
lution (10 mg/ml in PBS, i.v.; GoldBio) into anesthetized tumor-bearing 
mice. Bioluminescence from the luciferase-expressing tumor cells was deter-
mined using IVIS-SPECTRUM in vivo photon-counting device (Caliper 
Life Sciences). Images were quantified as photon counts/second using the 
Living Image software (Caliper Life Sciences).
Adoptive transfer of monocytes. In metastasis assay, CD11b+Ly6C+Ly6G– 
cells were sorted from BM monocytes isolated from WT or Ccl3/ mice 
and enriched by Monocyte Isolation kit (Miltenyi Biotec). Sorted cells (106) 
were injected with 5 × 105 of E0771-LG cells into mice transplanted with 
Ccl3/ BM cells. To chase the cell fate, monocytes were sorted from 
C57BL/6 or Ccr1/ mice and labeled with CellTracker CMFDA (Invitrogen) 
following the manufacturer’s instructions. The labeled monocytes (5 × 105) 
were transferred into C57BL/6 mice bearing pulmonary metastases. Pulmo-
nary tumor burdens in the recipients were determined by in vivo biolumi-
nescence imaging one day before monocyte transfer. The tumor-bearing 
mice were allocated to each group equally by their tumor loads. Some recip-
ient mice were treated with anti-integrin 4 antibodies (5 mg/kg body weight, 
i.p.; BioLegend) 18 h after transfer.
Flow cytometry and sorting. Single-cell suspensions were prepared from 
perfused lungs or blood samples as described previously (Qian et al., 2011). 
After blocking with anti–mouse CD16/CD32 antibody (BD), the cells were 
stained with DAPI and fluorescent antibodies to following antigens; CD45 
(30-F11), F4/80 (BM8), CD11b (M1/70), Ly6C (HK1.4), Gr1 (RB6-8C5), 
CD115 (AFS98), CD3 (17A2), NK1.1 (PK136; all from BioLegend); CD4 
(GK1.5), B2.20 (RA3-6B2), Ly6G (1A8), CD11c (HL3; all from BD); 
CD8a (53–6.7), CCR5 (7A4; both from eBioscience); CCR1 (643854), 
CCR2 (475301; both from R&D Systems). Flow cytometry was performed 
using LSRII cytometer (BD) and analyzed using FlowJo software (Tree Star). 
In some experiments, the stained cells were sorted using FACSAria II (BD).
Microarray analysis. We isolated MAMs (F4/80+ CD11b+) from the 
tumor-bearing lung by FACS Aria (BD) using above-mentioned antibodies. 
We also collected pulmonary resident macrophages (F4/80+ CD11c+) and 
splenic macrophages (F4/80+ CD11b+) from healthy mice. We extracted 
RNA from these cells and used it for hybridization on Nimblegen Mouse 
Gene Expression Array Chips. We performed ANOVA test to identify genes 
that are significantly (P < 0.01) changed in MAMs (more than threefold 
change) compared with resident macrophages. All gene expression datasets 
used in this study are available at the Gene Expression Omnibus accession 
no. GSE68862.
PCR. Expression of mRNA was determined by RT-PCR using Super-
Script III (Invitrogen) and ExTaq (Takara). All real-time PCR was performed 
on Opticon 2 qPCR (MJ Research) using SYBR master mix (Invitrogen). 
Primers used for real-time PCR are: mouse Gapdh, 5-AGAACATCAT-
CCCTGCATCC-3 and 5-CACATTGGGGGTAGGAACAC-3; mouse 
Ccl3, 5-ACCATGACACTCTGCAACCA-3 and 5-GATGAATTGGC-
GTGGAATCT-3; mouse Ccr1, 5-ACTCCACTCCATGCCAAAAG-3 
and 5-CTAGGACATTGCCCACCACT-3; mouse Ccr5, 5-CGAAAA-
CACATGGTCAAACG-3 and 5-GTTCTCCTGTGGATCGGGTA-3; 
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